Cargando…

An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance

BACKGROUND: Schizophrenia remains a priority condition in mental health policy and service development because of its early onset, severity and consequences for affected individuals and households. AIMS AND METHODS: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophr...

Descripción completa

Detalles Bibliográficos
Autores principales: Raykar, Neha, Nigam, Aditi, Chisholm, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938947/
https://www.ncbi.nlm.nih.gov/pubmed/27398070
http://dx.doi.org/10.1186/s12962-016-0058-z
_version_ 1782441931381407744
author Raykar, Neha
Nigam, Aditi
Chisholm, Dan
author_facet Raykar, Neha
Nigam, Aditi
Chisholm, Dan
author_sort Raykar, Neha
collection PubMed
description BACKGROUND: Schizophrenia remains a priority condition in mental health policy and service development because of its early onset, severity and consequences for affected individuals and households. AIMS AND METHODS: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophrenia treatment in India, which seeks to evaluate through a modeling approach not only the costs and health effects of intervention but also the consequences of a policy of universal public finance (UPF) on health and financial outcomes across income quintiles. RESULTS: Using plausible values for input parameters, we conclude that health gains from UPF are concentrated among the poorest, whereas the non-health gains in the form of out-of-pocket private expenditures averted due to UPF are concentrated among the richest income quintiles. Value of insurance is the highest for the poorest quintile and declines with income. CONCLUSIONS: Universal public finance can play a crucial role in ameliorating the adverse economic and social consequences of schizophrenia and its treatment in resource-constrained settings where health insurance coverage is generally poor. This paper shows the potential distributional and financial risk protection effects of treating schizophrenia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12962-016-0058-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4938947
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49389472016-07-10 An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance Raykar, Neha Nigam, Aditi Chisholm, Dan Cost Eff Resour Alloc Research BACKGROUND: Schizophrenia remains a priority condition in mental health policy and service development because of its early onset, severity and consequences for affected individuals and households. AIMS AND METHODS: This paper reports on an ‘extended’ cost-effectiveness analysis (ECEA) for schizophrenia treatment in India, which seeks to evaluate through a modeling approach not only the costs and health effects of intervention but also the consequences of a policy of universal public finance (UPF) on health and financial outcomes across income quintiles. RESULTS: Using plausible values for input parameters, we conclude that health gains from UPF are concentrated among the poorest, whereas the non-health gains in the form of out-of-pocket private expenditures averted due to UPF are concentrated among the richest income quintiles. Value of insurance is the highest for the poorest quintile and declines with income. CONCLUSIONS: Universal public finance can play a crucial role in ameliorating the adverse economic and social consequences of schizophrenia and its treatment in resource-constrained settings where health insurance coverage is generally poor. This paper shows the potential distributional and financial risk protection effects of treating schizophrenia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12962-016-0058-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-08 /pmc/articles/PMC4938947/ /pubmed/27398070 http://dx.doi.org/10.1186/s12962-016-0058-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Raykar, Neha
Nigam, Aditi
Chisholm, Dan
An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
title An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
title_full An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
title_fullStr An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
title_full_unstemmed An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
title_short An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance
title_sort extended cost-effectiveness analysis of schizophrenia treatment in india under universal public finance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938947/
https://www.ncbi.nlm.nih.gov/pubmed/27398070
http://dx.doi.org/10.1186/s12962-016-0058-z
work_keys_str_mv AT raykarneha anextendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance
AT nigamaditi anextendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance
AT chisholmdan anextendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance
AT raykarneha extendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance
AT nigamaditi extendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance
AT chisholmdan extendedcosteffectivenessanalysisofschizophreniatreatmentinindiaunderuniversalpublicfinance